Medical devices, healthcare technology and the business of care
PMA approval · P250042

BAGUERAC Cervical Disc Prosthesis

Spineart USA, Inc. · Decision date Aug 10, 2026

MEDTECHLEDGER EXPLANATIONP250042

What did the FDA approve?

The FDA approved the BAGUERA® C Cervical Disc Prosthesis from Spineart USA, Inc. on August 10, 2026. The approval covers reconstruction of the disc at one or two contiguous levels from C3-C7 after single-level or two-contiguous-level discectomy in skeletally mature patients with intractable radiculopathy or myelopathy.

Eligible conditions include herniated nucleus pulposus, spondylosis with osteophytes, or visible loss of disc height confirmed by imaging. Patients must have failed at least six weeks of non-operative treatment or have progressive symptoms. The device is implanted via an open anterior approach.

FDA approval order statement

The BAGUERA C Cervical Disc Prosthesis is indicated for use in skeletally mature patients for reconstruction of the disc at one or two contiguous levels from C3-C7 following single-level or two-contiguous-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to a single-level or two-contiguous-level abnormality localized to the level of the disc space and manifested by at least one of the following conditions confirmed by radiographic imaging (e.g., X-rays, computed tomography (CT), magnetic resonance imaging (MRI)): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. Patients receiving the BAGUERA C Cervical Disc Prosthesis should have failed at least six weeks of non-operative treatment or have the presence of progressive symptoms (e.g., numbness or tingling) prior to implantation. The BAGUERA C Cervical Disc Prosthesis is implanted via an open anterior approach.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Aug 10, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250042
Regulatory pathway
Premarket approval application
Product code
MJO
Decision code
APPR
Decision date
Aug 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, intervertebral disc.

Product code
MJO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250042 received

    Application receipt date recorded by FDA.

  2. P250042 · FDA decision

    APPR

  3. P250042/S002 · Related supplement

    BAGUERAC Cervical Disc Prosthesis

Timeline entries are records held by MedtechLedger for P250042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250042

Product / regulatory recordCompanyPathwayDecision dateSource
Spineart USA, Inc.PMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code MJO

Product / regulatory recordCompanyPathwayDecision dateSource
Synergy DiscP250028/S003
Synergy Spine Solutions, Inc.PMA supplementSep 17, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
prodisc C NovaP070001/S031
Centinel Spine, LLCPMA supplementSep 9, 2026FDA
Synergy Spine Solutions, Inc.PMA approvalFeb 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Spineart USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records